目的观察长春西汀注射液联合依达拉奉治疗急性腔隙性脑梗死的临床疗效。方法 96例急性腔隙性脑梗死患者随机分为观察组和对照组,各48例,两组在治疗相应基础病和常规抗凝、抗血小板聚集治疗基础上,观察组加用长春西汀注射液及依达拉奉进行治疗,对照组加用倍他司汀注射液及血塞通注射液进行治疗,疗程2周。观察两组治疗效果、记录不良反应、评估安全性。治疗前和治疗2周后进行欧洲脑卒中评分(ESS),用积分评判疗效。结果观察组总有效率为93.8%,优于对照组81.3%,差异具有统计学意义(P<0.05)。两组药物无明显不良反应。结论相比使用倍他司汀+血塞通,长春西汀联合依达拉奉治疗急性腔隙性脑梗死疗效确切,安全性好,值得临床推广应用。 Objective To observe the clinical efficacy of vinpocetine injection combined with edaravone in the treatment of acute lacunar infarction. Methods 96 patients with acute lacunar infarction were randomly divided into observation group and control group, 48 cases in each group. On the basis of the treatment of corresponding basic diseases and conventional anticoagulation and antiplatelet aggregation therapy, the observation group and Vinpocetine injection Fluid and edaravone for treatment, the control group plus betiostine injection and Xuesaitong injection for treatment, treatment for 2 weeks. The therapeutic effect was observed in both groups, adverse reactions were recorded and safety was assessed. The European Stroke Scale (ESS) was administered before treatment and after 2 weeks of treatment, and the scores were used to evaluate the efficacy. Results The total effective rate in the observation group was 93.8%, which was better than that in the control group (81.3%), the difference was statistically significant (P <0.05). Two groups of drugs without significant adverse reactions. Conclusions Compared with the use of betahistine + Xuesaitong, vinpocetine combined with edaravone in the treatment of acute lacunar infarction is effective, safe and worthy of clinical application.